Getinge AB (publ) (GETI-B.ST)
SEK 174.85
(2.01%)
SEK 174.85
(2.01%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 2.41 Billion SEK | -3.17% |
| 2022 | 2.49 Billion SEK | -16.13% |
| 2021 | 2.97 Billion SEK | -8.31% |
| 2020 | 3.23 Billion SEK | 165.06% |
| 2019 | 1.22 Billion SEK | 226.37% |
| 2018 | -967 Million SEK | -170.28% |
| 2017 | 1.37 Billion SEK | 15.82% |
| 2016 | 1.18 Billion SEK | -14.53% |
| 2015 | 1.39 Billion SEK | -3.0% |
| 2014 | 1.43 Billion SEK | -37.29% |
| 2013 | 2.28 Billion SEK | -9.36% |
| 2012 | 2.52 Billion SEK | -0.32% |
| 2011 | 2.52 Billion SEK | 11.07% |
| 2010 | 2.27 Billion SEK | 18.97% |
| 2009 | 1.91 Billion SEK | 25.67% |
| 2008 | 1.52 Billion SEK | 20.87% |
| 2007 | 1.26 Billion SEK | 0.48% |
| 2006 | 1.25 Billion SEK | 10.15% |
| 2005 | 1.13 Billion SEK | -0.82% |
| 2004 | 1.14 Billion SEK | 47.59% |
| 2003 | 777.7 Million SEK | 25.09% |
| 2002 | 621.7 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 513 Million SEK | 11.76% |
| 2024 Q3 | 2 Million SEK | -99.61% |
| 2024 Q1 | 459 Million SEK | -35.98% |
| 2023 Q1 | 586 Million SEK | 5.4% |
| 2023 Q4 | 717 Million SEK | -19.8% |
| 2023 Q3 | 894 Million SEK | 317.76% |
| 2023 Q2 | 214 Million SEK | -63.48% |
| 2023 FY | 2.41 Billion SEK | -3.17% |
| 2022 Q2 | 603 Million SEK | 12.92% |
| 2022 Q1 | 534 Million SEK | -30.83% |
| 2022 FY | 2.49 Billion SEK | -16.13% |
| 2022 Q4 | 556 Million SEK | -30.33% |
| 2022 Q3 | 798 Million SEK | 32.34% |
| 2021 Q1 | 644 Million SEK | -41.13% |
| 2021 FY | 2.97 Billion SEK | -8.31% |
| 2021 Q2 | 798 Million SEK | 23.91% |
| 2021 Q3 | 757 Million SEK | -5.14% |
| 2021 Q4 | 772 Million SEK | 1.98% |
| 2020 Q3 | 1.38 Billion SEK | 179.35% |
| 2020 FY | 3.23 Billion SEK | 165.06% |
| 2020 Q2 | 494 Million SEK | 82.29% |
| 2020 Q1 | 271 Million SEK | -70.06% |
| 2020 Q4 | 1.09 Billion SEK | -20.72% |
| 2019 Q4 | 905 Million SEK | 335.1% |
| 2019 Q3 | 208 Million SEK | 101.94% |
| 2019 Q1 | 6 Million SEK | -99.16% |
| 2019 FY | 1.22 Billion SEK | 226.37% |
| 2019 Q2 | 103 Million SEK | 1616.67% |
| 2018 Q3 | -1.45 Billion SEK | -1895.06% |
| 2018 FY | -967 Million SEK | -170.28% |
| 2018 Q1 | -307 Million SEK | -129.32% |
| 2018 Q2 | 81 Million SEK | 126.38% |
| 2018 Q4 | 713 Million SEK | 149.04% |
| 2017 Q4 | 1.04 Billion SEK | 1994.0% |
| 2017 Q3 | 50 Million SEK | 2400.0% |
| 2017 FY | 1.37 Billion SEK | 15.82% |
| 2017 Q2 | 2 Million SEK | -99.28% |
| 2017 Q1 | 277 Million SEK | -70.63% |
| 2016 Q4 | 943 Million SEK | 1196.51% |
| 2016 Q1 | 110 Million SEK | -88.52% |
| 2016 Q2 | 221 Million SEK | 100.91% |
| 2016 FY | 1.18 Billion SEK | -14.53% |
| 2016 Q3 | -86 Million SEK | -138.91% |
| 2015 FY | 1.39 Billion SEK | -3.0% |
| 2015 Q4 | 958 Million SEK | 453.76% |
| 2015 Q3 | 173 Million SEK | 1.76% |
| 2015 Q2 | 170 Million SEK | 88.89% |
| 2015 Q1 | 90 Million SEK | -90.97% |
| 2014 Q1 | -331 Million SEK | -126.78% |
| 2014 FY | 1.43 Billion SEK | -37.29% |
| 2014 Q4 | 997 Million SEK | 172.4% |
| 2014 Q3 | 366 Million SEK | -7.81% |
| 2014 Q2 | 397 Million SEK | 219.94% |
| 2013 Q4 | 1.23 Billion SEK | 199.27% |
| 2013 FY | 2.28 Billion SEK | -9.36% |
| 2013 Q3 | 413 Million SEK | -9.23% |
| 2013 Q2 | 455 Million SEK | 150.0% |
| 2013 Q1 | 182 Million SEK | -82.77% |
| 2012 Q2 | 530 Million SEK | 25.59% |
| 2012 Q3 | 518 Million SEK | -2.26% |
| 2012 Q4 | 1.05 Billion SEK | 103.86% |
| 2012 FY | 2.52 Billion SEK | -0.32% |
| 2012 Q1 | 422 Million SEK | -62.08% |
| 2011 Q3 | 511 Million SEK | 5.58% |
| 2011 FY | 2.52 Billion SEK | 11.07% |
| 2011 Q1 | 420 Million SEK | -52.86% |
| 2011 Q4 | 1.11 Billion SEK | 117.81% |
| 2011 Q2 | 484 Million SEK | 15.24% |
| 2010 Q3 | 496 Million SEK | 1.22% |
| 2010 Q2 | 490 Million SEK | 22.5% |
| 2010 Q1 | 400 Million SEK | -49.24% |
| 2010 FY | 2.27 Billion SEK | 18.97% |
| 2010 Q4 | 891 Million SEK | 79.64% |
| 2009 FY | 1.91 Billion SEK | 25.67% |
| 2009 Q3 | 412 Million SEK | 23.72% |
| 2009 Q4 | 788 Million SEK | 91.26% |
| 2009 Q1 | 382 Million SEK | 0.0% |
| 2009 Q2 | 333 Million SEK | -12.83% |
| 2008 FY | 1.52 Billion SEK | 20.87% |
| 2007 FY | 1.26 Billion SEK | 0.48% |
| 2006 FY | 1.25 Billion SEK | 10.15% |
| 2005 FY | 1.13 Billion SEK | -0.82% |
| 2004 FY | 1.14 Billion SEK | 47.59% |
| 2003 FY | 777.7 Million SEK | 25.09% |
| 2002 FY | 621.7 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 3198.704% |
| ADDvise Group AB (publ) | 103.5 Million SEK | -2230.435% |
| ADDvise Group AB (publ) | 103.5 Million SEK | -2230.435% |
| Arcoma AB | 2.56 Million SEK | -93971.763% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 1843.001% |
| BICO Group AB (publ) | -835.7 Million SEK | 388.62% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | -9556.884% |
| CellaVision AB (publ) | 130.3 Million SEK | -1750.985% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 3122.859% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | 8364.045% |
| C-Rad AB (publ) | 35.52 Million SEK | -6688.82% |
| Duearity AB (publ) | -26.19 Million SEK | 9309.622% |
| Dignitana AB (publ) | -17.36 Million SEK | 13991.609% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 2644.304% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 3648.244% |
| Iconovo AB (publ) | -45.89 Million SEK | 5355.608% |
| Integrum AB (publ) | 4.03 Million SEK | -59714.337% |
| Luxbright AB (publ) | -25.37 Million SEK | 9605.371% |
| Mentice AB (publ) | -2.81 Million SEK | 85723.003% |
| OssDsign AB (publ) | -130.49 Million SEK | 1948.375% |
| Paxman AB (publ) | 8.33 Million SEK | -28855.582% |
| Promimic AB (publ) | -9.22 Million SEK | 26254.847% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 1607.915% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 4439.3% |
| ScandiDos AB (publ) | -14.64 Million SEK | 16567.536% |
| Sectra AB (publ) | 428.38 Million SEK | -463.041% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 4146.165% |
| Senzime AB (publ) | -134.14 Million SEK | 1898.001% |
| SpectraCure AB (publ) | -20.44 Million SEK | 11899.814% |
| Stille AB | 26.64 Million SEK | -8952.015% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 162.633% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | -2526.879% |